VBI-1901 is a new cancer vaccine immunotherapeutic candidate that uses cytomegalovirus (CMV) as a foreign viral antigen approach to treat cancer by expressing two highly immunogenic CMV antigens,
The post VBI Vaccines gets orphan drug designation for glioblastoma therapy appeared first on Pharmaceutical Business review.